Display options
Cite
Siena G, Cindolo L, Ferrari G, et al. Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol. 2021;39(10):3875-3880doi: 10.1007/s00345-021-03642-4.
Siena, G., Cindolo, L., Ferrari, G., Maruzzi, D., Fasolis, G., Condorelli, S. V., Varvello, F., Visalli, F., Rabito, S., Toso, S., Caroassai, S., Mari, A., Viola, L., Somani, B. K., & Carini, M. (2021). Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World journal of urology, 39(10), 3875-3880. https://doi.org/10.1007/s00345-021-03642-4
Siena, Giampaolo, et al. "Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study." World journal of urology vol. 39,10 (2021): 3875-3880. doi: https://doi.org/10.1007/s00345-021-03642-4
Siena G, Cindolo L, Ferrari G, Maruzzi D, Fasolis G, Condorelli SV, Varvello F, Visalli F, Rabito S, Toso S, Caroassai S, Mari A, Viola L, Somani BK, Carini M. Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol. 2021 Oct;39(10):3875-3880. doi: 10.1007/s00345-021-03642-4. Epub 2021 Mar 31. PMID: 33787986; PMCID: PMC8010783.
Copy Download .nbib Format: NLM
Share it on

World J Urol. 2021 Oct;39(10):3875-3880. doi: 10.1007/s00345-021-03642-4. Epub 2021 Mar 31.

Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study.

World journal of urology

Giampaolo Siena, L Cindolo, G Ferrari, D Maruzzi, G Fasolis, S V Condorelli, F Varvello, F Visalli, S Rabito, S Toso, S Caroassai, A Mari, L Viola, B K Somani, M Carini

Affiliations

  1. Department of Urology, Careggi Hospital, University of Florence, San Luca Nuovo, Florence, Italy. [email protected].
  2. Department of Urology, Villa Stuart, Private Hospital, Rome, Italy.
  3. Department of Urology, Hesperia Hospital, Cure Group, Modena, Italy.
  4. Department of Urology, S. Maria Degli Angeli Hospital, Pordenone, Italy.
  5. Department of Urology, Michele e Pietro Ferrero Hospital, Alba-Bra, Italy.
  6. Department of Urology, Vittorio Emanuele Hospital, Gela, Italy.
  7. Department of Urology, Careggi Hospital, University of Florence, San Luca Nuovo, Florence, Italy.
  8. University Hospital Southampton NHS Trust, Tremona Road, Southampton, SO16 6YD, Hampshire, UK.

PMID: 33787986 PMCID: PMC8010783 DOI: 10.1007/s00345-021-03642-4

Abstract

PURPOSE: Rezūm is the latest developed minimally invasive treatment for benign prostatic hyperplasia (BPH). We aimed to carefully assess the functional outcomes of patients treated with Rezūm for BPH.

METHODS: We prospectively followed 135 consecutive patients treated by Rezūm at 5 institutions from June 2019 to August 2020. The International Prostate Symptom Score (IPSS), International Consultation on Incontinence Questionnaire-Short Form (ICIQ-UI SF), the Overactive Bladder Questionnaire-Short Form (OAB-q SF) score, the International Index of Erectile Function (IIEF-5) and questions 9 and 10 to assess ejaculatory dysfunction were recorded. Election criteria were age > 18, no prior prostate interventions, IPSS ≥ 13, post-void residual ≤ 250 mL, prostate volume between 30 and 120 cc.

RESULTS: The median operative time was 10.5 (IQR 8.7-15) min. All patients were dismissed few hours after surgery with indwelling urinary catheter that was removed after a median of 7 (IQR 7-10) days. A significantly decrease of IPSS from baseline at first (p = 0.001) and third (p < 0.0001) month after surgery was reported. No difference was reported in terms of ICIQ-UI SF score postoperatively. A mild reduction of the OAB-q SF score was reported at 1 month from surgery (p = 0.06) that turned significant at 3 months postoperatively (p < 0.0001). A slight but statistically significant increase of the IIEF-5 score was reported from baseline at 6 months (p = 0.04). Postoperatively, patients reported a significantly decrease of ejaculatory dysfunction after alpha-blocker interruption.

CONCLUSION: Rezūm treatment is a feasible minimally invasive option for patients with BPH symptoms and showed optimal early functional outcomes.

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords: Benign prostatic hyperplasia; Minimally invasive; Rezūm

References

  1. Issa MM, Fenter TC, Black L et al (2006) An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 12:S83-89 - PubMed
  2. Campbell FM, Walsh PC (2002) Urology, 8th edn. Saunders, pp 1297–1336 - PubMed
  3. Lee SWH, Chan EMC, Lai YK (2017) The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep 7:7984. https://doi.org/10.1038/s41598-017-06628-8 - PubMed
  4. Fitzpatrick JM (2006) The natural history of benign prostatic hyperplasia. BJU Int 97(Suppl 2):3–6. https://doi.org/10.1111/j.1464-410X.2006.06097.x (discussion 21-22) - PubMed
  5. Cindolo L, Pirozzi L, Fanizza C et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68:418–425. https://doi.org/10.1016/j.eururo.2014.11.006 - PubMed
  6. Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR (2019) The Rezūm system–a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. Can J Urol 26:9787–9793 - PubMed
  7. McVary KT, Rogers T, Roehrborn CG (2019) Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled Study. Urology 126:171–179. https://doi.org/10.1016/j.urology.2018.12.041 - PubMed
  8. Suzuki T, Otsuka A, Ozono S (2016) Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 23:929–933. https://doi.org/10.1111/iju.13188 - PubMed
  9. Green Z, Westwood J, Somani BK (2019) What’s new in rezum: a transurethral water vapour therapy for BPH. Curr Urol Rep 20:39. https://doi.org/10.1007/s11934-019-0903-7 - PubMed
  10. Zlotta AR, Giannakopoulos X, Maehlum O et al (2003) Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44:89–93. https://doi.org/10.1016/s0302-2838(03)00218-5 - PubMed
  11. Mattiasson A, Wagrell L, Schelin S et al (2007) Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 69:91–96. https://doi.org/10.1016/j.urology.2006.08.1115 (discussion 96-97) - PubMed
  12. Mynderse LA, Roehrborn CG, Partin AW et al (2011) Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol 185:1804–1810. https://doi.org/10.1016/j.juro.2010.12.054 - PubMed
  13. Roehrborn CG, Barkin J, Gange SN et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24:8802–8813 - PubMed
  14. Misrai V, Rijo E, Zorn KC et al (2019) Waterjet ablation therapy for treating benign prostatic obstruction in patients with small- to medium-size glands: 12-month results of the first French aquablation clinical registry. Eur Urol 76:667–675. https://doi.org/10.1016/j.eururo.2019.06.024 - PubMed
  15. Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR (2015) Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 7:13–18. https://doi.org/10.2147/RRU.S74040 - PubMed
  16. Mynderse LA, Hanson D, Robb RA et al (2015) Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 86:122–127. https://doi.org/10.1016/j.urology.2015.03.021 - PubMed
  17. McVary KT, Gange SN, Gittelman MC et al (2016) Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 195:1529–1538. https://doi.org/10.1016/j.juro.2015.10.181 - PubMed
  18. Jones P, Rajkumar GN, Rai BP et al (2016) Medium-term outcomes of urolift (Minimum 12 Months Follow-up): evidence from a systematic review. Urology 97:20–24. https://doi.org/10.1016/j.urology.2016.05.003 - PubMed
  19. Jones P, Rai BP, Nair R, Somani BK (2015) Current status of prostate artery embolization for lower urinary tract symptoms: review of world literature. Urology 86:676–681. https://doi.org/10.1016/j.urology.2015.05.011 - PubMed
  20. Taktak S, Jones P, Haq A et al (2018) Aquablation: a novel and minimally invasive surgery for benign prostate enlargement. Ther Adv Urol 10:183–188. https://doi.org/10.1177/1756287218760518 - PubMed
  21. Roehrborn CG, Teplitsky S, Das AK (2019) Aquablation of the prostate: a review and update. Can J Urol 26:20–24 - PubMed
  22. Johnston MJ, Noureldin M, Abdelmotagly Y et al (2020) Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int. https://doi.org/10.1111/bju.15203 - PubMed
  23. Rocco B, Sighinolfi MC, Sandri M et al (2020) The dramatic COVID 19 outbreak in Italy is responsible of a huge drop of urological surgical activity: a multicenter observational study. BJU Int. https://doi.org/10.1111/bju.15149 - PubMed
  24. Gratzke C, Barber N, Speakman MJ et al (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119:767–775. https://doi.org/10.1111/bju.13714 - PubMed
  25. Reale G, Marchioni M, Altieri V et al (2020) Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urol Nefrol 72:622–628. https://doi.org/10.23736/S0393-2249.20.03597-3 - PubMed

Publication Types